ASH Clinical News May 2015 | Page 26

24 Latest & Greatest study, researchers tested two compounds (MI-463 and MI-503) in cell lines and in mice with MLL leukemia. The compounds blocked the MLL-menin interaction without harming normal blood cells. Both compounds were delivered into the blood and metabolized at a good rate. Source: University of Michigan Health System press release; Borkin D, He S, Miao H, et al. Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015;27:589-602. FDA Panel Votes in Favor of Cangrelor for Blood Clot Prevention Cangrelor, a P2Y12 inhibitor under investigation as an antiplatelet drug for use during percutaneous coronary interventions, was recently recommended for approval by the FDA’s Cardiovascular and Renal Drugs Advisory Committee. The panel voted 9-2 (with one abstention) in favor of a narrow antithrombotic indication as an adjunct to PCI for reducing risk of periprocedural ischemic complications. This was a reversal from the 2-7 vote the drug received recommending against drug approval during an initial panel meeting in February 2014. Panelists who voted in favor of approval cited a relatively small benefit with cangrelor but also a smaller risk than clopido- Summary of Prescribing Information BLINCYTO™ (blinatumomab) for injection, for intravenous use WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES grel, another P2Y 12 inhibitor approved for use during PCI. Several panelists expressed concerns that cangrelor’s approval could change practice by giving clinicians a convenient, although no better and possibly less effective, alternative to preloading. They called for the FDA to reflect such concerns in the label if it does follow their recommendation for approval. Source: FDA Briefing Document observed in approximately 25% of patients, some of which were life-threatening or fatal. As appropriate, administer prophylactic antibiotics and employ surveillance testing during treatment with BLINCYTO™. Monitor patients for signs and symptoms of infection and treat appropriately. 5.4 Tumor Lysis Syndrome • Cytokine Release Syndrome (CRS), which may be lifethreatening or fatal, occurred in patients receiving BLINCYTO™. Interrupt or discontinue BLINCYTO™ as recommended. [See Dosage and Administration (2.3), Warnings and Precautions (5.1)]. • Neurological toxicities, which may be severe, lifethreatening, or fatal, occurred in patients receiving BLINCYTO™. Interrupt or discontinue BLINCYTO™ as recommended. [See Dosage and Administration (2.3), Warnings and Precautions (5.2)]. Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has been observed in patients receiving BLINCYTO™. Appropriate prophylactic measures, including pretreatment nontoxic cytoreduction and ontreatment hydration, should be used for the prevention of TLS during BLINCYTO™ treatment. Monitor for signs or symptoms of TLS. Management of these events may require either temporary interruption or discontinuation of BLINCYTO™ [see Dosage and Administration (2.3)]. 1. Neutropenia and febrile neutropenia, including lifethreatening cases, have been observed in patients receiving BLINCYTO™. Monitor laboratory parameters (including, but not limited to, white blood cell count and absolute neutrophil count) during BLINCYTO™ infusion. Interrupt BLINCYTO™ if prolonged neutropenia occurs. INDICATIONS AND USAGE BLINCYTO™ is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials [see Clinical Studies (14.1)]. 4. CONTRAINDICATIONS 5.5 Neutropenia and Febrile Neutropenia 5.6 Effects on Ability to Drive and Use Machines Due to the potential for neurologic events, including seizures, patients receiving BLINCYTO™ are at risk for loss of consciousness [see Warnings and Precautions (5.2)]. Advise patients to refrain from driving and engaging in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while BLINCYTO™ is being administered. • Effects on Ability to Drive and Use Machines [see Warnings and Precautions (5.6)] • Elevated Liver Enzymes [see Warnings and Precautions (5.7)] • Leukoencephalopathy [see Warnings and Precautions (5.8)] • Preparation and Administration Errors [see Warnings and Precautions (5.9)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data described in this section reflect exposure to BLINCYTO™ in clinical trials in which 212 patients with relapsed or refractory ALL received up to 28 mcg/day. All patients received at least one dose of BLINCYTO™. The median age of the study population was 37 years (range: 18 to 79 years), 63% were male, 79% were White, 3% were Asian, and 3% were Black or African American. The most common adverse reactions (≥ 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%). 5.1 Cytokine Release Syndrome 5.7 Elevated Liver Enzymes Serious adverse reactions were reported in 65% of patients. The most common serious adverse reactions (≥ 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion, Staphylococcal bacteremia, and headache. Cytokine Release Syndrome (CRS), which may be lifethreatening or fatal, occurred in patients receiving BLINCYTO™. Treatment with BLINCYTO™ was associated with transient elevations in liver V秖